Oral lisaftoclax for slow-growing B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an oral medication called lisaftoclax for people with slow-growing B-cell lymphomas, such as CLL, Waldenström's macroglobulinemia, or marginal zone lymphoma. It may be an option if you haven't had treatment yet but can't take standard BTK inhibitor pills, or if you tried one BTK inhibitor and had to stop because of side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of these slow-growing lymphomas: chronic lymphocytic leukemia (CLL), Waldenström's macroglobulinemia (WM), or marginal zone lymphoma (MZL).
- If you haven't had treatment yet, you must be unable to take standard BTK inhibitor pills due to other health problems. Or, you must have tried only one BTK inhibitor and had to stop it because of side effects.
- Your blood counts must be within a certain range: hemoglobin ≥ 70 g/L (without transfusions in the last week), platelets ≥ 50×10⁹/L (or ≥ 30 if bone marrow involved), and absolute neutrophils ≥ 0.5×10⁹/L.
- Your liver and kidney function must be adequate, with creatinine clearance ≥ 40 ml/min and liver enzymes within 2.5 times the upper limit of normal.
- You must not have had a blood clot in your leg or lung in the past year, and you must not have active infections like hepatitis B, hepatitis C, or HIV (unless well-controlled).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies APG-2575 (alone or with other medicines) in adults with CLL/SLL whose disease came back or did not respond to earlier treatment. The goal is to learn the safest dose and whether it can shrink the leukemia and improve symptoms.
This trial tests a new drug called APG2575 for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have been taking a BTK inhibitor for at least 12 months. The goal is to see if adding APG2575 can help control the disease better.
This trial tests a new combination of two targeted drugs (lisaftoclax and acalabrutinib) against standard chemo-immunotherapy for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment. It aims to see if the combination works better.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
This trial tests a combination of pomalidomide, an antibody that targets a protein on B cells, and a steroid to treat slow-growing B-cell lymphomas. If you have not yet been treated and meet the health criteria, this could be an option to consider.
Hear when a new Indolent Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.